The Board of Directors of Wntresearch AB ("WntResearch") has resolved to bring forward the publication of the interim report for the first quarter 2020 to 17 April 2020. The previously disclosed date of publication was 19 May 2020. The Board of Directors of WntResearch has further resolved to postpone the publication of the annual report for 2019 to 16 April 2020. The previously disclosed date of publication was during week 13, 2020. In addition to the above, the Board of Directors of WntResearch has resolved to postpone the Annual General Meeting to 8 June 2020 instead of 19 May 2020 as previously disclosed. The AGM will be held in Malmö. Time and place for the AGM will be announced when the notice convening the AGM is issued at the latest.
For more information, please contact:
Peter Morsing, CEO, WntResearch AB
Telephone: +46 727 200711
The information was submitted for publication, through the agency of the contact person set out above, on 24 March 2020.
WntResearch is developing an entirely new kind of cancer drug, which inhibits the tumour cells' ability to spread through the body and metastasize. The majority of cancer deaths are due to metastases, and there are no therapies available that can prevent that. Foxy-5, the Company's most advanced drug candidate, is a peptide that mimics the body's own WNT5A protein. In preclinical trials, Foxy-5 has demonstrated ability to suppress the mobility and invasive power of cancer cells, and thus to inhibit metastasis. Phase 1 studies on patients with colon, prostate and breast cancer have demonstrated a good safety profile and favourable pharmacokinetics, and early data indicates biological activity. A Phase 2 multicenter study is underway on patients with colon cancer, in order to study the anti-metastasizing efficacy of Foxy-5. WntResearch's share is listed on Spotlight Stock Market. For more information, please visit: www.wntresearch.com